Financial Performance - The company incurred net losses of $45.1 million and $55.8 million for the years ended December 31, 2019 and 2018, respectively, with an accumulated deficit of $83.5 million as of December 31, 2019[142]. - The company expects to continue incurring substantial net losses and negative cash flows from operations as it commercializes its gammaCore therapy[143]. - As of December 31, 2019, the company had cash and cash equivalents of $13.6 million and marketable securities of $10.5 million, indicating potential liquidity challenges[144]. - The company may need to seek additional funds in the future to support its commercialization efforts and research and development activities, which could impact its growth[146]. Market and Regulatory Challenges - The company relies heavily on third-party payers for adequate coverage and reimbursement for gammaCore therapy, which is essential for revenue generation[155]. - The lack of sufficient and timely coverage and reimbursement could adversely affect the demand for the company's products and its revenues[157]. - The company faces regulatory challenges as its products are not currently covered by Medicare and Medicaid, which could impact its commercialization strategy[159]. - The ongoing COVID-19 pandemic has significantly restricted economic activity, potentially affecting the company's business operations and revenues[161]. - The company has closed its New Jersey office and warehouse due to state-imposed restrictions related to the coronavirus outbreak, impacting its operational capabilities[164]. - Sales and marketing efforts with the VA and DoD are adversely affected by recent protocols for screening and restricting outside visitors and vendors[165]. - The company is unable to reasonably estimate the impact of the novel coronavirus outbreak on its business, revenues, financial condition, and results of operations, but the impact could be significantly negative[166]. Commercialization and Sales Strategy - The commercialization strategy may expose the company to increased billing, cash application, and credit risks due to the high cost of claims and complex billing requirements[168]. - Revenues from the sale of gammaCore therapy depend on the continued availability of reimbursement by government and private insurance plans, which involves a complex and time-consuming billing and collection process[169]. - The company faces challenges in obtaining coverage and reimbursement for gammaCore therapy under pharmacy benefit plans, which has hindered its commercialization strategy[171]. - The company must demonstrate the medical and economic benefits of gammaCore therapy compared to competitors' products to gain physician support and market acceptance[173]. - The company’s operating results may vary significantly from quarter to quarter due to factors such as physician and payer acceptance, timing of payer coverage, and seasonal variations in headache attacks[178]. Clinical Trials and Development - The company must overcome significant challenges in developing and commercializing its product candidates, including regulatory approval and market acceptance[176]. - Conducting clinical trials in the United States may incur significantly higher costs compared to foreign clinical trials, potentially impacting the company's financial condition[189]. - The company relies on patient enrollment for clinical trials; insufficient enrollment could delay research and development efforts, increasing costs and hindering product development timelines[190]. - Factors affecting patient enrollment include eligibility criteria, perceived risks and benefits, competition for patients, and the design of the trial[191]. - Delays in clinical trials could increase expenses and slow down the approval process for the gammaCore therapy, jeopardizing future revenue generation[195]. - The company has postponed certain clinical trials as part of a comprehensive redeployment plan and cost reduction strategy implemented in June 2019[197]. - The FDA or other regulatory bodies may suspend or terminate clinical trials due to various factors, including safety concerns and noncompliance with regulations[199]. Competition and Market Position - The company faces significant competition in the cluster headache (CH) and migraine markets, with established competitors having advantages such as larger sales forces and greater financial resources[215]. - The company has a limited commercial track record for its gammaCore therapy, which has been available for approximately two years in the United States, compared to traditional products that have been available for decades[219]. - Sales of gammaCore outside the United States represented a substantial portion of the company's net sales in 2019 and 2018, indicating reliance on international markets[221]. - The company must establish and strengthen its brand to achieve market acceptance of gammaCore therapy, which may require significant marketing expenses[229]. Intellectual Property and Legal Risks - The company may become involved in costly and time-consuming lawsuits to protect its intellectual property, which could hinder commercialization efforts[267]. - The success of the company depends on securing effective patent protection, which is expensive and time-consuming[268]. - The company may not be able to accurately estimate or control future operating expenses related to intellectual property, leading to potential cash shortfalls[273]. - The company may face challenges in obtaining necessary patents, which could allow competitors to market similar products without incurring significant development costs[269]. - Changes in patent laws and their interpretations may adversely affect the company's ability to protect its intellectual property rights[277]. - The company may face challenges to its patents, which could result in invalidation or limitations on their enforceability, impacting business objectives[280]. - Legal means provide limited protection for proprietary rights, and competitors may develop superior products not covered by existing patents[281]. Operational and Management Challenges - Future acquisitions may increase capital requirements and subject the company to risks such as increased operating expenses and dilution of stockholders[183]. - The company has reduced its direct salesforce, which may affect its ability to market and sell gammaCore therapy effectively in the United States[210]. - Future growth will require significant management resources to recruit, train, and integrate additional employees, which may strain the company's operational infrastructure[208]. - The company may encounter difficulties with manufacturing and supply chain issues, potentially leading to delays in the availability of gammaCore therapy and increased expenses[207]. - The company is dependent on retaining key executives and attracting new talent, with potential turnover risks due to unvested equity awards losing value[236]. - Effective succession planning is crucial for the company's long-term success, especially following the appointment of a new CEO in October 2019[239]. Compliance and Regulatory Environment - The company is subject to a wide variety of regulatory compliance requirements as a federal contractor, and failure to comply could adversely impact future contracts[251]. - The company faces risks related to government regulations that could delay the marketing of new products and impose costly procedures[324]. - The medical device industry is heavily regulated, with oversight from the FDA and other international regulatory agencies affecting all aspects of product development and marketing[330]. - The company must ensure adequate training for users and secure reimbursement for procedures performed with its products to support market acceptance[328].

electroCore, Inc. (NASDAQ:ECOR) Q4 2019 Earnings Conference Call March 23, 2020 4:45 PM ET Company Participants Hans Vitzthum - Investor Relations Dan Goldberger - Chief Executive Officer Brian Posner - Chief Financial Officer Conference Call Participants Ryan Zimmerman - BTIG Craig Bijou - Cantor Fitzgerald Swayampakula Ramakanth - H.C. Wainwright Ahu Demir - Noble Capital Operator Greetings. Welcome to electroCore’s Fourth Quarter and Full Year 2019 Earnings Conference Call. At this time all participants ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED September 30, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM ______________ TO ______________ Commission File Number 001-38538 electroCore, Inc. (Exact name of Registrant as specified in its charter) Delaware 20-345497 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED June 30, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM ______________ TO ______________ Commission File Number 001-38538 electroCore, Inc. (Exact name of Registrant as specified in its charter) Delaware 20-3454976 (St ...

electroCore, Inc. (NASDAQ:ECOR) Q2 2019 Results Conference Call August 13, 2019 4:30 PM ET Company Participants Hans Vitzthum - LifeSci Advisors Frank Amato - Chief Executive Officer Brian Posner - Chief Financial Officer Tony Fiorino - Chief Medical Officer Conference Call Participants Ahu Demir - Noble Capital Josh Schimmer - Evercore Operator Good day, ladies and gentlemen. And welcome to electroCore Second Quarter Earnings Conference Call and Webcast. Currently, at this time, all participants are in lis ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM ______________ TO ______________ Commission File Number 001-38538 electroCore, Inc. (Exact name of Registrant as specified in its charter) Delaware 20-3454976 (S ...

electroCore, Inc. (NASDAQ:ECOR) Q1 2019 Earnings Conference Call May 14, 2019 4:30 PM ET Company Participants Hans Vitzthum - LifeSci Advisors Frank Amato - Chief Executive Officer Brian Posner - Chief Financial Officer Tony Fiorino - Chief Medical Officer JP Errico - Founder Conference Call Participants Josh Schimmer - Evercore ISI Dave Turkaly - JMP Securities Marie Thibault - BTIG Ahu Demir - Noble Capital Market Operator Greetings, and welcome to electroCore First Quarter 2019 Earnings Conference Call. ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38538 electroCore, Inc. (Exact name of Registrant as specified in its Charter) Delaware 20-3454976 (State or other jurisdiction of in ...

electroCore, Inc. (NASDAQ:ECOR) Q4 2018 Results Earnings Conference Call March 27, 2019 4:30 PM ET Company Participants Hans Vitzthum - LifeSci Advisors Frank Amato - CEO J.P. Errico - Chief Science and Strategy Officer Glenn Vraniak - CFO Conference Call Participants Vijay Kumar - Evercore ISI Charles Duncan - Cantor Marie Thibault - BTIG Dave Turkaly - JMP Securities Operator Greetings, and welcome to electroCore Fourth Quarter and Fiscal Year 2018 Earnings Conference Call. [Operator Instructions] Please ...